Circular Genomics is a biotechnology company specializing in RNA-based diagnostics and therapeutics for psychiatric and neurological diseases. Founded in 2021 and headquartered in Albuquerque, New Mexico, the company focuses on developing innovative assays to improve the treatment of complex brain disorders. Their core mission is to leverage circular RNA technology to create more effective diagnostic tools and personalized treatment approaches.
The company has made significant strides in its field, particularly in predicting patient responses to SSRI antidepressant treatments using circRNA-based tests. This breakthrough has the potential to revolutionize mental health treatment by enabling more targeted and effective therapies. Circular Genomics continues to expand its expertise, as evidenced by the addition of Dr. Michael Ackermann to its Scientific Advisory Board, further strengthening its position in the biotechnology sector.
